医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Multi-Lactobacillus BARU Developed by GSL-BIO Showed Excellent Effects on Environmental Improvement

2019年07月22日 PM08:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

BARU, the multi-lactobacillus developed by a Korean microorganism company GSL-BIO, has been proven to improve water quality drastically.

BARU is a multi-lactobacillus made of seed microorganism that was developed by fermenting natural herbs such as Houttuynia cordata, green tea, and black ginseng which are native to Korea, using original technology in a patented culture facility.

It contains a total of 12 kinds of bacteria including 9 lactobacillus and 3 fungus and is highly effective in removing green algae.

BARU has a remarkable decomposing capability and survivability which enables some of them to endure high temperatures exceeding 100℃. There are no side effects even if it is used repeatedly because it doesn’t accumulate in the body nor the soil nearby.

BARU showed an immensely positive result in a trial application to fisheries. It reduced the mortality rate of fishery products and promoted their growth by cutting down their stress and improving the immune system. Besides, harmful bacteria, ammonia, and nitrous acid in the water and the amount of water required to be changed are significantly reduced to improve the water quality. The product is extremely helpful not just to fishery but also to the agricultural and livestock industries.

“Water pollution is one of the most urgent challenges that needs to be cleared by a global effort,” said Young-mi Kim, a director of GSL LAB where BARU was developed. “Fermented lactobacillus are expected to be a great solution to water pollution.”

More information on the multi-lactobacillus BARU, please visit http://gslbio.com/en/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190722005029/en/

CONTACT

GSL-Bio Co., Ltd

Kyung-hwan Oh, +82-64-794-2334

gslbio@daum.net

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • LetsGetChecked首发经FDA EUA核准的居家冠状病毒(COVID-19) Sure-track检测
  • FDA Accepts Shionogi’s Supplemental New Drug Application with Priority Review for FETROJA® (cefiderocol) for the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
  • LetsGetChecked、FDAのEUA承認を受けた在宅型コロナウイルス(COVID-19)検査用シュア・トラック・テストを発表
  • 欧盟委员会同意武田无需履行剥离夏尔后续化合物SHP647的承诺
  • Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time